Discover the power of real-time signals plus AI
Every funding round, exec hire, M&A move, contract, and sentiment shift on hC Bioscience, Inc. — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Round Type
series a
Description
hC Bioscience, Inc., a company developing first-in-class tRNA-based therapeutics targeting protein dysfunction in genetically defined diseases, today announced an extension of $16 million to its Series A funding round, bringing the total raised to $40 million. Taiho Ventures and Panacea Venture joined existing investors, ARCH Venture Partners, Takeda Ventures and 8VC.
Related People
Sign in to view contact details
Sign in to view contact details
Watching hC Bioscience, Inc.? See every signal — funding, hires, M&A, contracts, sentiment.
See plans